The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...